ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria

SABCS 2017

2017-12-05 - 2017-12-09
San Antonio, United States

ESMO 2017

2017-09-08 - 2017-09-12
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark

ASCO 2016

2016-06-03 - 2016-06-07
Chicago, United States

ELCC 2016

2016-04-13 - 2016-04-16
Geneva, Switzerland
Search in Scientific Content:
Date
Filters:
New develo
9:19

New developments in neurendocrine tumours

Presenter: Jennifer Chan
ESMO 2024
Adjuvant P
4:21

Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial Carcinoma

Presenter: Petros Grivas
ESMO 2024
Randomized
4:18

Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer

Presenter: Petros Grivas
ESMO 2024
Substantia
6:56

Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in Previously Treated HER2-positive mBC Including a Large Cohort of Patients with Brain Metastases

Presenter: Giampaolo Bianchini
ESMO 2024
Breast can
16:34

Breast cancer, metastatic highlights of the ESMO 2024 Congress

Presenter: Giampaolo Bianchini
ESMO 2024
RCC highli
5:25

RCC highlights of ESMO 2024 Congress

Presenter: Camillo Porta
ESMO 2024
Efficacy o
3:18

Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression on an Androgen-Receptor Pathway Inhibitor

Presenter: Oliver Sartor
ESMO 2024
Prostate C
4:03

Prostate Cancer highlights of ESMO 2024 Congress

Presenter: Oliver Sartor
ESMO 2024
Radiation
3:60

Radiation therapy for breast cancer can be safely shortened by changing technique

Presenter: Sofia Rivera
ESMO 2024
Melanoma h
15:55

Melanoma highlights of the ESMO 2024 Congress

Presenter: Jessica Hassel
ESMO 2024
Quadruplet
4:57

Quadruplet therapy is becoming the new standard of treatment - Multiple myeloma highlights at ESMO2024

Presenter: Xavier Leleu
ESMO 2024
Lymphoma h
11:37

Lymphoma highlights of the ESMO 2024 Congress

Presenter: Maria Gomes da Silva
ESMO 2024
LEAP-012 S
5:09

LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib + Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma

Presenter: Josep M. Llovet
ESMO 2024
Pembrolizu
4:39

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Presenter: Domenica Lorusso
ESMO 2024
Lung cance
6:07

Lung cancer interception: New approaches to lung cancer screening and prevention

Presenter: Jianjun Zhang
ESMO 2024
Genitourin
8:17

Genitourinary tumours, non-prostate highlights of the ESMO 2024 Congress

Presenter: Aristotelis Bamias
ESMO 2024
Effects of
11:15

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Presenter: Richard Gray
Specialty: Breast Cancer
Alpelisib
14:48

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Presenter: Dejan Juric
Specialty: Breast Cancer
Lifestyle
8:40

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Presenter: Wolfgang Janni
Specialty: Breast Cancer
Choice of
8:39

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Presenter: Laura Dominici
Specialty: Breast Cancer
Circulatin
10:32

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Presenter: Francois-Clement Bidard
Specialty: Breast Cancer
Axillary R
9:45

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Presenter: Emiel J. T. Rutgers
Specialty: Breast Cancer
Accelerate
6:19

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Presenter: Fank Vicini
Specialty: Breast Cancer
A randomiz
10:32

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

Presenter: Andrea De Censi
Specialty: Breast Cancer
PALLET: A
12:51

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Presenter: Mitchell Dowsett
Specialty: Breast Cancer
Phase III
9:33

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Presenter: Charles E. Geyer, Jr
Specialty: Breast Cancer
Adjuvant C
8:05

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Presenter: Miguel Martín
Specialty: Breast Cancer
Adjuvant C
7:33

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Presenter: Laura Spring
Specialty: Breast Cancer
Delaying A
5:48

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Presenter: Zaida Morante
Specialty: Breast Cancer
Low-Dose T
9:12

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Presenter: Andrea De Censi
Specialty: Breast Cancer
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Specialty: Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Specialty: Breast Cancer
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Interrupti
1:17

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Presenter: Matteo Lambertini
The issue
1:15

The issue of adjuvant vs neoadjuvant treatment

Presenter: Paolo A. Ascierto
The treatm
1:19

The treatment sequence in metastatic melanoma

Presenter: Paolo A. Ascierto
Functional
1:19

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
The first
1:10

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
First-line
7:41

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Presenter: Ken Kato